NCT03882918View on ClinicalTrials.gov

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

PHASE3TerminatedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

June 4, 2021

Study Completion Date

June 30, 2021

Conditions
Angelman Syndrome
Interventions
DRUG

OV101

Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.

Trial Locations (11)

19063

Ovid Therapeutics Investigative Site, Media

30322

Ovid Therapeutics Investigative Site, Atlanta

32123

Ovid Therapeutics Investigative Site, San Diego

37212

Ovid Therapeutics Investigative Site, Nashville

45229

Ovid Therapeutics Investigative Site, Cincinnati

52621

Ovid Therapeutics Investigative Site, Ramat Gan

60612

Ovid Therapeutics Investigative Site, Chicago

85006

Ovid Therapeutics Investigative Site, Phoenix

98405

Ovid Therapeutics Investigative Site, Tacoma

02115

Ovid Therapeutics Investigative Site, Boston

02421

Ovid Therapeutics Investigative Site, Lexington

Sponsors

Lead Sponsor

Healx AI
All Listed Sponsors
lead

Healx AI

INDUSTRY

NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome | Biotech Hunter | Biotech Hunter